UNSPSC 51201574: Palivizumab

A humanized monoclonal antibody (IgG1? ) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).

UNSPSC 51201574 Palivizumab is a Commodity code that nominally designates a respiratory syncytial virus (RSV) prophylaxis pharmaceutical; however, the recent state and local opportunities tagged to this code show no alignment with palivizumab procurement and instead reflect general medical supply, athletic training services, and pharmacy benefit management exploration. The code shows minimal relevant recent activity — the three posted opportunities relate to athletic training services for police and fire departments, first-aid supply procurement for a fire rescue department, and a request for information regarding direct-to-manufacturer pharmacy initiatives, none of which involve palivizumab or RSV immunization products.

The mismatch between the code's nominal scope and the actual opportunities posted against it indicates either a cataloging or tagging error on the issuing bodies' part or a broad misapplication of the commodity code to medical procurement generally. State and local governments pursuing palivizumab or related RSV prophylaxis products should verify the correct UNSPSC code in their target agencies' historical procurement records or contact issuing bodies directly rather than relying on this code's recent activity as a procurement signal. The three visible opportunities — the City of Tucson's RFP for athletic training services (due June 9, 2026), the City of Tampa Fire Rescue's ITB for medical aid supplies (originally posted for April 2025), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer pharmacy programs (April 3, 2026) — serve jurisdictions in Arizona, Florida, and Texas but do not represent palivizumab procurement and should not be pursued under this code designation.